Comparison · NCT01814332-3ca16752
GSK561679 vs Placebo: Safety, Measured by the Number of Subjects That Experienced an Adverse Event
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. GSK561679 vs Placebo: Safety, Measured by the Number of Subjects That Experienced an Adverse Event. Trial comparisons, record NCT01814332-3ca16752. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01814332-3ca16752
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.873 | 0.769 | 0.934 | wilson | |
| Risk in group 2 | 0.846 | 0.739 | 0.914 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0269 | -0.0975 | 0.15 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.03 | 0.897 | 1.19 | log | |
| Odds ratio, group 1 over group 2 | 1.25 | 0.459 | 3.4 | log | |
| Number needed to treat, for one more participant with the outcome on GSK561679 than on Placebo | 37.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | GSK561679 | GSK561679, oral administration, 350mg/day, 6 week administration~GSK561679: GSK561679, oral administration, 350mg/day, 6 week administration | 55 | 63 | OG000 |
| Group 2 | Placebo | Placebo compound treatment for comparison with IP~Placebo: Placebo compound treatment for comparison with IP | 55 | 65 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Safety, Measured by the Number of Subjects That Experienced an Adverse Event
- Description
- The occurrence of adverse events will be recorded at the end of 6 weeks.
- Time frame
- Baseline, Week 6
- Population
Source ClinicalTrials.gov
Trial
- Title
- Analyzing Female Trauma Exposed Responses to a Medication
- NCT number
- NCT01814332
- Phases
- PHASE2
- Conditions
- Stress Disorders, Post-traumatic
- Interventions
- GSK561679, Placebo
- Lead sponsor
- VA Office of Research and Development
- Results first posted
- 2016-04-25
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01814332?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01814332-3ca16752